Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Noncoding RNAs in chronic wound healing: Mechanisms, exosome therapeutics, and translational frontiers

Yang L., Lv Y.

Narrative Review on Chronic Wound, published in J Tissue Eng (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Tissue Eng (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41509512
PMCID
PMC12775362
DOI
10.1177/20417314251410000
Citations
1

Abstract (original English)

Chronic wounds have become major clinical problems due to dysregulated inflammation, impaired angiogenesis, and abnormal extracellular matrix (ECM) remodeling. Noncoding RNA (ncRNA), including microRNA (miRNA), long noncoding RNA (lncRNA), and circular RNA (circRNA), serve as key molecules to regulate these pathological processes. These ncRNA also constructs a competitive endogenous RNA (ceRNA) network to precisely adjust miRNA activity and target gene expression. Through gene editing or chemical modification, exosomes achieve ncRNA delivery with high efficiency and targeting and show exciting promise in preclinical models. Combining with biomaterials such as hydrogels can prolong the exosome half-life and achieve the continuous release of ncRNA. In addition, researchers explore how machine learning (ML) and artificial intelligence (AI) could advance future therapeutic applications. Drug delivery system can be improved both by predicting personalized ceRNA networks for individual patients, and designing smart wound dressings that combine exosomes with hydrogel materials tailored to specific wound types. By integrating these recent advances, this review helps bridge basic research and the future creation of targeted chronic wound treatments.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research